Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Does COVID-19 Confer Risk for Venous Thromboembolism in Ambulatory Patients?
A U.K. study suggests that it does, particularly in unvaccinated patients.
Nonimmune Hemolysis in Myelodysplastic Syndromes
Patients with MDS and nonimmune hemolysis were more likely to have EZH2 and U2AF1 mutations.
Immunotherapy Regimen for EGFR-Mutated Non–Small-Cell Lung Cancer
A four-drug regimen — sintilimab, IBI305, pemetrexed, and cisplatin — improved survival, with no new safety signals.
FOLFOXIRI/Panitumumab No Better Than FOLFOX/Panitumumab for Colorectal Cancer
The triplet regimen did not improve response rate or survival and was more toxic.
Adjuvant Immunotherapy for Locally Advanced Kidney Cancer: The Saga Continues
Adjuvant atezolizumab was not associated with a disease-free survival benefit compared with placebo in the IMmotion010 trial.
More Information on Disease Associations with Sickle Cell Trait
Among Black people in the U.K., sickle cell trait was associated with diabetes, hypertension, chronic renal disease, and retinal disorders.
Disparities in Clinical Trial Enrollment for Hematologic Malignancies
Some racial and ethnic populations were under-represented in pivotal trials leading to FDA drug approvals.
Strong Pathologic Complete Response to Immunotherapy in MSI-High Esophagogastric Cancer
This landmark study indicates a high degree of pathologic complete response to neoadjuvant treatment with ipilimumab and nivolumab.
Phase 1 Oncology Trials: Improved Outcomes Over Time
Overall response rates in these trials nearly doubled from 2000 to 2019, without an increase in treatment-related death.